Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors

Archives of General Psychiatry

Volumn 63, Issue 8, 2006, Pages 907-915

  Brody, Arthur L ^a,b   Mandelkern, Mark A ^b,c   London, Edythe D ^a,b   Olmstead, Richard E ^b   Farahi, Judah ^b   Scheibal, David ^a,b   Jou, Jennifer ^a,b   Allen, Valerie ^a,b   Tiongson, Emmanuelle ^a,b   Chefer, Svetlana I ^d   Koren, Andrei O ^e   Mukhin, Alexey G ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR; BRAIN RECEPTOR; FLUORO 3 (2 AZETIDINYLMETHOXY) PYRIDINE FLUORODEOXYFLUCOSE F 18; FLUORODEOXYGLUCOSE F 18; NICOTINE; NICOTINIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BRAIN METABOLISM; CIGARETTE SMOKING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DESENSITIZATION; FEMALE; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN SECRETION; SATIETY; SMOKING CESSATION; WITHDRAWAL SYNDROME;

ADULT; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NICOTINE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECEPTORS, NICOTINIC; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME; TISSUE DISTRIBUTION; TOBACCO USE DISORDER;

EID: 33746922400     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.8.907     Document Type: Article

References (69)

1. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. JAMA. 2001;285:535-539.
2. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847-852.
3. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaén CR, Kottke TE, Lando HA, Mecklenburg RE, Mullen PD, Nett LM, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, Md: US Dept of Health and Human Services, Public Health Service; 2000.
4. Ashenden R, Silagy C, Weller D. A systematic review of the effectiveness of promoting lifestyle change in general practice. Fam Pract. 1997;14:160-176.
5. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
6. Henningfield JE, Fant RV. Tobacco use as drug addiction: the scientific foundation. Nicotine Tob Res. 1999;1(suppl 2):S31-S35.
7. Cohen C, Pickworth WB, Henningfield JE. Cigarette smoking and addiction. Clin Chest Med. 1991;12:701-710.
8. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177-184.
9. West R, Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving. Psychopharmacology (Berl). 2001;155:115-122.
10. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol. 2004;4:36-46.
11. Ernst M, Heishman SJ, Spurgeon L, London ED. Smoking history and nicotine effects on cognitive performance. Neuropsychopharmacology. 2001;25:313-319.
12. Mendrek A, Monterosso J, Simon SL, Jarvik M, Brody A, Olmstead R, Domier CP, Cohen MS, Ernst M, London ED. Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Addict Behav. 2006;31:833-844.
13. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S. International Union of Pharmacology, XX: current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51:397-401.
14. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274-5278.
15. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382:255-257.
16. Sziraki, Lipovac MN, Hashim A, Sershen H, Allen D, Cooper T, Czobor P, Lajtha A. Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res. 2001;26:609-617.
17. Damsma G, Day J, Fibiger HC. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol. 1989;168:363-368.
18. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 1994;653:278-284.
19. Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotineinduced excitability of brain reward areas. Neuron. 2002;33:905-919.
20. Leshner AI, Koob GF. Drugs of abuse and the brain. Proc Assoc Am Physicians. 1999;111:99-108.
21. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029-1032.
22. Picciotto MR, Zoli M, Changeux JP. Use of knock-out mice to determine the molecular basis for the actions of nicotine. Nicotine Tob Res. 1999;1(suppl 2):S121-S125.
23. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol. 2004;65:1526-1535.
24. Liu X, Koren AO, Yee SK, Pechnick RN, Poland RE, London ED. Self-administration of 5-iodo-A-85380, a beta 2-selective nicotinic receptor ligand, by operantly trained rats. Neuroreport. 2003;14:1503-1505.
25. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, Dufour N, Cloez-Tayarani I, Bemelmans AP, Mallet J, Gardier AM, David V, Faure P, Granon S, Changeux JP. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103-107.
26. Sihver W, Nordberg A, Langstrom B, Mukhin AG, Koren AO, Kimes AS, London ED. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res. 2000;113:143-157.
27. Benowitz NL, Porchet H, Jacob PI. Pharmacokinetics, metabolism, and pharmacodynamics of nicotine. In: Wonnacott S, Russell MAH, Stolerman IP, eds. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects. Oxford, England: Oxford University Press; 1990:112-157.
28. Koren AO, Horti AG, Mukhin AG, Gundisch D, Kimes AS, Dannals RF, London ED. 2-, 5-, and 6-halo-3-(2(S)-azetidinylmethoxy)pyridines. J Med Chem. 1998;41:3690-3698.
29. Chefer SI, London ED, Koren AO, Pavlova OA, Kurian V, Kimes AS, Horti AG, Mukhin AG. Graphical analysis of 2-[F-18]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse. 2003;48:25-34.
30. Gallezot JD, Bottlaender M, Gregoire MC, Roumenov D, Deverre JR, Coulon C, Ottaviani M, Dolle F, Syrota A, Valette H. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med. 2005;46:240-247.
31. Valette H, Bottlaender M, Dolle F, Coulon C, Ottaviani M, Syrota A. Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J Neurochem. 2003;84:105-111.
32. Ding YS, Volkow ND, Logan J, Garza V, Pappas N, King P, Fowler JS. Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette. Synapse. 2000;35:234-237.
33. Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[18F]fluoro-A-85380 in human PET imaging studies. Nucl Med Biol. 2005;32:869-874.
34. Mitkovski S, Villemagne VL, Novakovic KE, O'Keefe G, Tochon-Danguy H, Mulligan RS, Dickinson KL, Saunder T, Gregoire MC, Bottlaender M, Dolle F, Rowe CC. Simplified quantification of nicotinic acetylcholine receptors with 2[18F]F-A-85380 PET. Nucl Med Biol. 2005;32:585-591.
35. Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, Friello P, Koren AO, Kurian V, Matochik JA, Pavlova O, Vaupel DB, Mukhin AG. 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 2003;17:1331-1333.
36. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
37. Fagerström KO. Measuring the degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3:235-241.
38. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.
39. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
40. Spielberger C. Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologists Press; 1983.
41. Shiffman SM, Jarvik ME. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl). 1976;50:35-39.
42. Carson RE. PET physiological measurements using constant infusion. Nucl Med Biol. 2000;27:657-660.
43. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P. Comparison of bolus and infusion methods for receptor quantitation. J Cereb Blood Flow Metab. 1993;13:24-42.
44. US Federal Trade Commission. "Tar," Nicotine, and Carbon Monoxide of the Smoke of 1294 Varieties of Domestic Cigarettes for the Year 1998. Washington, DC: US Federal Trade Commission; 2000.
45. Jacob P III, Wilson M, Benowitz NL. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr. 1981;222:61-70.
46. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL. Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav. 2000;66:553-558.
47. Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR Jr, Madsen D, Jarvik ME. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry. 2002;59:1162-1172.
48. Dhawan V, Kazumata K, Robeson W, Belakhlef A, Margouleff C, Chaly T, Nakamura T, Dahl R, Margouleff D, Eidelberg D. Quantitative brain PET: comparison of 2D and 3D acquisitions on the GE Advance Scanner. Clin Positron Imaging. 1998;1:135-144.
49. Doll F, Dolci L, Valette H, Hinnen F, Vaufrey F, Guenther I, Fuseau C, Coulon C, Bottlaender M, Crouzel C. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2- azetidinylmethoxypyridine. J Med Chem. 1999;42:2251-2299.
50. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 1993;17:536-546.
51. London ED, Waller SB, Wamsley JK. Autoradiographic localization of [3H]nicotine binding sites in the rat brain. Neurosci Lett. 1985;53:179-184.
52. Villemagne VL, Horti A, Scheffel U, Ravert HT, Finley P, Clough DJ, London ED, Wagner HN Jr, Dannals RF. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J Nucl Med. 1997;38:1737-1741.
53. Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A, Seneca N, Tipre D, DeNucci CC, Iida H, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP, Baldwin RM, Innis RB. Quantification of nicotinic acetylcholine receptors in human brain using [I-123]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging. 2003;30:1620-1629.
54. Valette H, Bottlaender M, Dolle F, Guenther I, Coulon C, Hinnen F, Fuseau C, Ottaviani M, Crouzel C. Characterization of the nicotinic ligand 2-[F-18]fluoro-3-[2 (S)-2-azetidinylmethoxy]pyridine in vivo. Life Sci. 1999;64:PL93-PL97.
55. Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med. 2001;42:755-763.
56. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79-115.
57. Paradiso KG, Steinbach JH. Nicotine is highly effective at producing desensitization of rat alpha4beta2 neuronal nicotinic receptors. J Physiol. 2003;553:857-871.
58. Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. J Neurobiol. 2002;53:457-478.
59. Benwell ME, Balfour DJK, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem. 1988;50:1243-1247.
60. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC, Leonard S. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther. 1997;282:7-13.
61. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci. 2004;7:583-584.
62. Zhang H, Sulzer D. Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci. 2004;7:581-582.
63. Robinson ML, Houtsmuller EJ, Moolchan ET, Pickworth WB. Placebo cigarettes in smoking research. Exp Clin Psychopharmacol. 2000;8:326-332.
64. Chefer SI, Mukhin AG, Horti AG, Koren AD, Pavlova OI, Kurian V, Stratton M, Kimes AS, London ED. 2-[18F]-fluoro-a-85380. In: Proceedings of the International Conference on Mathematics and Engineering Techniques in Medicine and Biology. 2000:409-415.
65. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23-29.
66. Luck W, Nau H, Hansen R, Steldinger R. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther. 1985;8:384-395.
67. Becker AB, Manfreda J, Ferguson AC, Dimich-Ward H, Watson WT, Chan-Yeung M. Breast-feeding and environmental tobacco smoke exposure. Arch Pediatr Adolesc Med. 1999;153:689-691.
68. Jarvis MJ, Russell MA, Feyerabend C. Absorption of nicotine and carbon monoxide from passive smoking under natural conditions of exposure. Thorax. 1983;38:829-833.
69. Jarvis MJ. Uptake of environmental tobacco smoke. IARC Sci Publ. 1987;(87):43-58.